340B Drug Pricing Reform Could Ripple Into Medicaid Drug Pricing Dynamics
Milliman's white paper examines the rapid growth of the 340B Drug Pricing Program and CMS's proposed CY2027 OPPS rule to cut Medicare Part B 340B drug payments, noting the program's deep interconnection with Medicaid Best Price requirements and Medicare Maximum Fair Price policy. While the analysis is primarily focused on Medicare outpatient reimbursement and hospital financial impacts, it flags downstream effects relevant to drug pricing stakeholders broadly, including those managing Medicaid pharmacy benefit and rebate calculations. Medicaid managed care plans with pharmacy benefit responsibilities may need to track these reforms given the programs' interlocking statutory ceiling price mechanics.
This is outside commentary from Milliman, not part of Medicaid Monitor's independently scored news coverage.